MannKind Corporation (MNKD) Earnings Call Transcripts

MannKind Corporation's Latest Earnings Call - May 29, 2026

MannKind Corporation's Q2 2026 earnings call was marked by the significant milestone of FDA approval for Afrezza in pediatric patients aged 6 and older. This approval is expected to drive future growth, with management highlighting the potential for Afrezza to become a standard in pediatric diabetes care. Revenue and earnings figures were not disclosed in this call, as the focus was on the strategic implications of the approval. Management did not provide specific financial guidance changes but emphasized the long-term growth potential from the pediatric market.

Reported metrics

Guidance from management

Management did not provide specific financial guidance but emphasized the long-term growth potential from the pediatric market and anticipated significant revenue contributions starting in 2027.

What management said

Thank you, Ben, and thanks for coming late on a Friday here. I think June will kind of start to get the early foundation laid out here. But I would say we want to see probably a quarter behind us, see how many prescribers come into the fold, how many repeat patients we get. So I think you'll start to see it build in Q3 and ultimately Q4 to set us up for a really nice '27.

And then the other thing Nick's going to be doing is we've got centers of excellence, 5 every week or 2, we're going to be launching. And that's going to work out any kinks that we identify in the first 30 days. So that's another key part of the launches, figuring out where we may have missed something or how we self-correct as we continue to evolve each week.

What analysts pressed on

Analysts questioned the speed at which pediatric sales will impact overall revenue and the potential pricing dynamics over time. Concerns were also raised about the ability to streamline the prescription process and ensure smooth patient access.

Main topics on the call

• FDA Approval for Pediatric Use — Afrezza is now approved for children aged 6 and older, covering 95% of children diagnosed with type 1 diabetes. This marks a major milestone as it is the first alternative to mealtime injections in over a century for ped...
• Clinical Data and Efficacy — Afrezza demonstrated a 35% reduction in postprandial glucose excursion compared to multiple daily injections in pivotal trials. The pediatric trial showed consistent results with adults, supporting its efficacy in childr...
• Launch Strategy — The launch will focus on pediatric endocrinologists, with a concentrated effort on 60 key institutions. MannKind plans to leverage existing clinical trial relationships to drive adoption.
• Market Opportunity — The addressable market includes 360,000 children and young adults with type 1 diabetes. Management anticipates significant revenue potential, estimating $300 million to $500 million from the pediatric segment.

Read the full MannKind Corporation transcript (May 29, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 45 MannKind Corporation earnings call transcripts on record, spanning February 25, 2020 to July 29, 2026. Based on this history, MannKind Corporation reports quarterly. The most recent call on file is dated July 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MNKD

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

45

First call

February 25, 2020

Most recent

July 29, 2026

Reporting cadence

quarterly